Search
Now showing items 1-10 of 17
Rolling out antiretrovirals in Africa: there are still challenges ahead
(Infectious Diseases Society of America, 2005-08)
In their article “Lessons Learned from Highly Active Antiretroviral Therapy in Africa,” Akileswaran et al. [1] review the effectiveness of HAART programs in Africa. They report positive health outcomes, including high ...
Factors influencing the acceptance of directly observed therapy in the delivery of anti-retroviral drugs for treatment of Human Immunodeficiency Virus in Urban Uganda
(2008-05)
Background: Directly observed therapy for highly active antiretroviral therapy (DOT-HAART) has the potential to improve adherence and social support in HIV+ patients. Aims were to determine; the level of DOT-HAART acceptance, ...
HIV immune reconstitution syndrome in sub-Saharan Africa
(Lippincott Williams & Wilkins, 2008)
Over the last 5 years, there has been remarkable progress
in providing HAART to patients in developing countries.
In sub-Saharan Africa alone, the number receiving antiretroviral
therapy (ART) has more than doubled in ...
Factors affecting adherence to cotrimoxazole prophylaxis among HIV/AIDS patients in Rukungiri District, Uganda.
(2009)
INTRODUCTION:
Globally, 33 million people are estimated to be living with HIV of which 22 million are in sub Saharan Africa. In Rukungiri district, 20115 people were estimated to be living with HIV/AIDS. With adherence ...
Evaluation of patients' response to treatment with highly active antiretroviral therapy at the Infectious Diseases Institute, Kampala.
(2009-10)
BACKGROUND:
In Africa, a consideration number of clients get diagnosed with HIV for the first time after a WHO stage 4 illness. Evidence in the developed world shows that individuals who initiate ART with advanced HIV/AIDS ...
Antiretroviral therapy improves cognitive impairment in HIV individuals in Sub-Saharan Africa
(American Academy of Neurology (AAN), 2006)
Abstract—Background: Highly active antiretroviral therapy (HAART) can improve cognitive performance in some patients
with HIV-associated cognitive impairment in the United States. The effect of HAART on HIV dementia ...
In vivo PPD reactivity and associated factors among HIV positive patients on HAART at the Makerere University Infectious Diseases Clinic.
(2009-08)
BACKGROUND:
It is estimated that a third of the world’s population is infected with tuberculosis (TB).
This epidemic is fueled by HIV, with reactivation rates of 8-10% / year and overall lifetime risk of 30% in HIV ...
Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy
(CID, 2008)
Background. Cryptococcal meningitis (CM) is the proximate cause of death in 20%–30% of persons with acquired immunodeficiency syndrome in Africa. Methods. Two prospective, observational cohorts enrolled human immunodeficiency ...
Coping with TB immune reconstitution inflammatory syndrome
(Expert Reviews, 2009)
The TB immune reconstitution inflammatory syndrome (IRIS) is a relatively frequent complication in HIV–TB-coinfected patients after they start highly active antiretroviral therapy (HAART). There are two forms of TB IRIS: ...
Longitudinal antiretroviral adherence in HIV+ Ugandan parents and their children initiating HAART in the MTCT-plus family treatment model: role of depression in declining adherence over time.
(Springer, 2009-03-20)
We conducted a study to assess the effect of family-based treatment on adherence amongst HIV-infected parents and their HIV-infected children attending the Mother-To-Child-Transmission Plus program in Kampala, Uganda. ...